Vitamin D 3 regulates LAMP3 expression in monocyte derived dendritic cells

Malaguarnera, Mariano; Marsullo, Anna Rita; Zorena, Katarzyna; Musumeci, Giuseppe; Rosa, Michelino Di

doi:10.1016/j.cellimm.2016.09.013

Cited by 24 publications

(24 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…128 Its ability to target DCs is one of the latest novelties in the field of vitamin D biology, highlighted as a pro-tolerogenic molecule. The immunomodulatory action of vitamin D may be closely associated with the immunoregulatory role of mesenchymal stem cells because they upregulate only the programmed cell-death receptor 1 in tolerant DCs, yet not VDR.…”

Section: Role In Inflammationmentioning

confidence: 99%

The Role of Vitamin D in the Immune System as a Pro-survival Molecule

Chirumbolo

Bjørklund

Sboarina

et al. 2017

Clinical Therapeutics

106

View full text Add to dashboard Cite

show abstract

Section: Role In Inflammationmentioning

confidence: 99%

The Role of Vitamin D in the Immune System as a Pro-survival Molecule

Chirumbolo

Bjørklund

Sboarina

et al. 2017

Clinical Therapeutics

106

View full text Add to dashboard Cite

show abstract

“…LAMP3 is a protein encoded by the LAMP3 gene in humans. 17 LAMP3 is highly expressed in differentiated and mature dendritic cells, 18 as well as many cancer cell types, including esophageal cancer, cervical cancer, and breast cancer. [12][13][14][15] Reportedly, LAMP3 has a number of diverse functions including hepatic lipid metabolism 19 and is associated with Bipolar disorder and Schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Down-Regulation of LAMP3 Inhibits the Proliferation and Migration of HSCC

Qiu

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lysosomal-associated membrane glycoprotein 3 (LAMP3) has been shown to be highly expressed in various types of tumors. It is associated with their poor prognosis, proliferation, invasion, and metastasis, respectively. However, the role of LAMP3 in hypopharyngeal squamous cell carcinoma (HSCC) is unclear. Objective:This article aims to investigate the role of LAMP3 in the proliferation and metastasis of HSCC. Method: Detection of the expression of LAMP3 in clinical HSCC and paired adjacent healthy tissue samples by using immunohistochemistry. Furthermore, LAMP3 was knocked out of the HSCC cell line, FaDu, using a lentivirus vector and the in vitro biological effects of LAMP3 knockdown in FaDu cells were studied. Results: Immunohistochemistry results showed that LAMP3 was highly expressed in HSCC. Additionally, it was verified at the mRNA and protein levels that lentiviral transduction effectively down-regulated the expression of LAMP3 in FaDu cells. Cell colony formation assays and CCK8 proliferation assays showed that down-regulation of LAMP3 on FaDu cells inhibited cell proliferation and growth rate. Wound healing experiments and transwell experiments showed that significant down-regulation of LAMP3 on FaDu cells inhibited cell migration. Conclusion:Collectively, our results suggest that LAMP3 is a useful therapeutic target for the treatment of hypopharyngeal cancer.

show abstract

“…The tolerogenic-inducing properties of 1,25-dihydroxycholecalciferol, the active form of vitamin D3, over DC (vitD3-tolDC) have been widely reported in vitro in many studies performed with murine ( 67 – 70 ) and even cattle cells ( 71 ), although we will only focus on biomarkers of human vitD3-tolDC ( 20 , 23 , 27 , 32 , 33 , 36 , 37 , 41 , 44 , 61 – 64 , 72 – 74 ). As a measurement of its relevance, such is the importance of vitD3-tolDC in the field of tolerogenic cell products that even two clinical trials are already ongoing for the treatment of multiple sclerosis using this cell product in Badalona, Spain ( http://www.clinicaltrials.gov , NCT02903537) and in Antwerp, Belgium ( http://www.clinicaltrials.gov , NCT02618902).…”

Section: Tolerogenic Dendritic Cells As Key Tolerance-inducing Playermentioning

confidence: 99%

“…As a measurement of its relevance, such is the importance of vitD3-tolDC in the field of tolerogenic cell products that even two clinical trials are already ongoing for the treatment of multiple sclerosis using this cell product in Badalona, Spain ( http://www.clinicaltrials.gov , NCT02903537) and in Antwerp, Belgium ( http://www.clinicaltrials.gov , NCT02618902). Several transcriptomic and proteomic pre-clinical studies in human vitD3-tolDC have evidenced several genes and proteins strongly induced with this approach, including immune-related molecules— CCL22 ( 62 , 63 ), ILT3 (immunoglobulin-like transcript 3) ( 36 ), CD300LF ( 62 ) or GILZ ( 32 ), these last two in common with dexa-tolDC—and oxidative metabolism enzymes and regulators— GLUT3 (glucose transporter 3), LDHA (lactate dehydrogenase A), mTOR (mammalian target of rapamycin), PDHA1 (pyruvate dehydrogenase E1, subunit alpha 1) or PFKFB4 (fructose-2,6-bisphosphatase) ( 63 )—, as well as direct targets of the response to vitamin D3 through the interaction with its receptor, like CYP24A1 (cytochrome P450, family 24, subfamily A, member 1) ( 41 , 61 – 63 ) and of course VDR (vitamin D receptor) ( 41 ). By their part, the repression of several co-stimulatory, pro-inflammatory, and antigen presenting genes and molecules like CD1A, CD1C, CD80, FSCN1 or the transcription factor IRF4 has been reported at the transcriptomic and proteomic levels ( 37 , 62 ).…”

Section: Tolerogenic Dendritic Cells As Key Tolerance-inducing Playermentioning

confidence: 99%

Searching for the Transcriptomic Signature of Immune Tolerance Induction—Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages

2018

View full text Add to dashboard Cite

The last years have witnessed a breakthrough in the development of cell-based tolerance-inducing cell therapies for the treatment of autoimmune diseases and solid-organ transplantation. Indeed, the use of tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg) is currently being tested in Phase I and Phase II clinical trials worldwide, with the aim of finding an effective therapy able to abrogate the inflammatory processes causing these pathologies without compromising the protective immunity of the patients. However, there exists a wide variety of different protocols to generate human tolDC and Mreg and, consequently, the characteristics of each product are heterogeneous. For this reason, the identification of biomarkers able to define their functionality (tolerogenicity) is of great relevance, on the one hand, to guarantee the safety of tolDC and Mreg before administration and, on the other hand, to compare the results between different cell products and laboratories. In this article, we perform an exhaustive review of protocols generating human tolDC and Mreg in the literature, aiming to elucidate if there are any common transcriptomic signature or potential biomarkers of tolerogenicity among the different approaches. However, and although several effectors seem to be induced in common in some of the most reported protocols to generate both tolDC or Mreg, the transcriptomic profile of these cellular products strongly varies depending on the approach used to generate them.

show abstract

Vitamin D 3 regulates LAMP3 expression in monocyte derived dendritic cells

Cited by 24 publications

References 45 publications

The Role of Vitamin D in the Immune System as a Pro-survival Molecule

The Role of Vitamin D in the Immune System as a Pro-survival Molecule

Down-Regulation of LAMP3 Inhibits the Proliferation and Migration of HSCC

Searching for the Transcriptomic Signature of Immune Tolerance Induction—Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages

Contact Info

Product

Resources

About